Soluble Guanylate Cyclase Stimulators and Activators: New Horizons in the Treatment of Priapism Associated with Sickle Cell Disease

Overview

Journal Front Pharmacol

Date 2024 Feb 22

PMID 38384294

Authors

Dalila Andrade Pereira

Tammyris Helena Rebecchi Silveira

Fabiano Beraldi Calmasini

Fabio Henrique Silva

Affiliations

Soon will be listed here.

Abstract

Priapism, defined as a prolonged and often painful penile erection occurring without sexual stimulation or desire, is a common complication in sickle cell disease (SCD), affecting up to 48% of male patients. This condition presents significant clinical challenges and can lead to erectile dysfunction if not properly managed. Current pharmacological treatments for SCD-related priapism are primarily reactive rather than preventative, highlighting a gap in effective medical intervention strategies. A critical factor in developing priapism is the reduced basal bioavailability of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) in erectile tissues. New prevention strategies should ideally target the underlying pathophysiology of the disease. Compounds that stimulate and activate soluble guanylate cyclase (sGC) emerge as potential therapeutic candidates since these compounds have the property of inducing cGMP production by sGC. This review explores the potential of sGC stimulators and activators in treating priapism associated with SCD. We discuss the advantages of these agents in the face of the challenging pathophysiology of SCD. Additionally, the review underscores the impact of intravascular hemolysis and oxidative stress on priapism pathophysiology in SCD, areas in which sGC stimulators and activators may also have beneficial therapeutic effects.

References

Kavanagh P, Fasipe T, Wun T . Sickle Cell Disease: A Review. JAMA. 2022; 328(1):57-68. DOI: 10.1001/jama.2022.10233. View

Bivalacqua T, Musicki B, Hsu L, Gladwin M, Burnett A, Champion H . Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med. 2009; 6(9):2494-504. PMC: 4011713. DOI: 10.1111/j.1743-6109.2009.01359.x. View

Anele U, Mack A, Resar L, Burnett A . Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature. Int Urol Nephrol. 2014; 46(9):1733-1736. PMC: 4335636. DOI: 10.1007/s11255-014-0737-7. View

Lagoda G, Sezen S, Hurt K, Cabrini M, Mohanty D, Burnett A . Sustained nitric oxide (NO)-releasing compound reverses dysregulated NO signal transduction in priapism. FASEB J. 2013; 28(1):76-84. PMC: 4046159. DOI: 10.1096/fj.13-228817. View

Adeyoju A, Olujohungbe A, Morris J, Yardumian A, Bareford D, Akenova A . Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int. 2002; 90(9):898-902. DOI: 10.1046/j.1464-410x.2002.03022.x. View

Bivalacqua T, Allen B, Brock G, Broderick G, Chou R, Kohler T . The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline. J Urol. 2022; 208(1):43-52. DOI: 10.1097/JU.0000000000002767. View

Pacher P, Beckman J, Liaudet L . Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007; 87(1):315-424. PMC: 2248324. DOI: 10.1152/physrev.00029.2006. View

Silva F, Karakus S, Musicki B, Matsui H, Bivalacqua T, Dos Santos J . Beneficial Effect of the Nitric Oxide Donor Compound 3-(1,3-Dioxoisoindolin-2-yl)Benzyl Nitrate on Dysregulated Phosphodiesterase 5, NADPH Oxidase, and Nitrosative Stress in the Sickle Cell Mouse Penis: Implication for Priapism Treatment. J Pharmacol Exp Ther. 2016; 359(2):230-237. PMC: 5074485. DOI: 10.1124/jpet.116.235473. View

Cita K, Brureau L, Lemonne N, Billaud M, Connes P, Ferdinand S . Men with Sickle Cell Anemia and Priapism Exhibit Increased Hemolytic Rate, Decreased Red Blood Cell Deformability and Increased Red Blood Cell Aggregate Strength. PLoS One. 2016; 11(5):e0154866. PMC: 4856257. DOI: 10.1371/journal.pone.0154866. View

10.

Kaul D, Liu X, Chang H, Nagel R, Fabry M . Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004; 114(8):1136-45. PMC: 522244. DOI: 10.1172/JCI21633. View

11.

GLOVER R, Ivy E, Orringer E, Maeda H, Mason R . Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol. 1999; 55(6):1006-10. DOI: 10.1124/mol.55.6.1006. View

12.

Kato G, Piel F, Reid C, Gaston M, Ohene-Frempong K, Krishnamurti L . Sickle cell disease. Nat Rev Dis Primers. 2018; 4:18010. DOI: 10.1038/nrdp.2018.10. View

13.

Tchernychev B, Li H, Lee S, Gao X, Ramanarasimhaiah R, Liu G . Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease. Br J Pharmacol. 2021; 178(17):3463-3475. PMC: 8453770. DOI: 10.1111/bph.15492. View

14.

Lagoda G, Sezen S, Cabrini M, Musicki B, Burnett A . Molecular analysis of erection regulatory factors in sickle cell disease associated priapism in the human penis. J Urol. 2012; 189(2):762-8. PMC: 4478587. DOI: 10.1016/j.juro.2012.08.198. View

15.

Decaluwe K, Pauwels B, Boydens C, Thoonen R, Buys E, Brouckaert P . Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice. J Sex Med. 2017; 14(2):196-204. DOI: 10.1016/j.jsxm.2016.12.007. View

16.

Teixeira C, Priviero F, Webb R . Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type,.... J Pharmacol Exp Ther. 2007; 322(3):1093-102. DOI: 10.1124/jpet.107.124594. View

17.

Aslan M, Ryan T, Adler B, Townes T, Parks D, Thompson J . Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 2001; 98(26):15215-20. PMC: 65009. DOI: 10.1073/pnas.221292098. View

18.

Monica F, Antunes E . Stimulators and activators of soluble guanylate cyclase for urogenital disorders. Nat Rev Urol. 2017; 15(1):42-54. DOI: 10.1038/nrurol.2017.181. View

19.

Reiter C, Wang X, Tanus-Santos J, Hogg N, Cannon 3rd R, Schechter A . Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002; 8(12):1383-9. DOI: 10.1038/nm1202-799. View

20.

Pereira D, Pereira D, da Silva Pereira P, Silveira T, Calmasini F, Reis L . Hydroxyurea does not reverse functional alterations of the nitric oxide-cGMP pathway associated with priapism phenotype in corpus cavernosum from sickle cell mouse. PLoS One. 2023; 18(10):e0292706. PMC: 10561851. DOI: 10.1371/journal.pone.0292706. View